Fig. 3: DMRTA2 expression is upregulated in human glioma cells, in particular in sphere cultures enriched in glioma stem cells.
From: DMRTA2 supports glioma stem-cell mediated neovascularization in glioblastoma
A Western blot showing DMRTA2 protein levels in established glioma cells (LN18, U87MG, T98G, LN229), patient-derived (WG4, WG1) glioma cell cultures and normal human astrocytes (NHA). B Densitometry analysis of Western blot for DMRTA2 protein expression in normal human astrocytes (NHA), established (LN18, U87MG, T98G, LN229) and patient-derived (WG4, WG1) glioma cell lines (2–3 biological replicates for each cell line). C Quantification of DMRTA2 expression in LN18 adherent cells and LN18-derived spheres by qRT-PCR (n = 3 biological replicates). *p < 0.05. D Representative immunoblot showing the DMRTA2 protein levels in LN18 cells and LN18-derived spheres. E Immunofluorescence for DMRTA2 in LN18 adherent cells and LN18-derived spheres (n = 3 biological replicates). Nuclei visualized with DAPI, scale bar—50 µm. Of note is uniform, nuclear expression of DMRTA2 in most LN18 glioma sphere-forming cells, while in adherent cells DMRTA2 is visible in a cytoplasm and rare cells.
